Kedrion Biopharma expands its commitment in Turkey
Expansion plans revealed at Embassy reception in Ankara on October 14
4ID – Kedrion proud to support new App for patients with Immunodeficiencies
Our company restates its long-standing and consistent collaboration with IPOPI
KIDCARES10, First Patient Treated in Pediatric PI Study
Thirty patients aged 2 to 17yo to be enrolled over five European countries
Kedrion stronger in North America and further committed to rare diseases
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
Kedrion Biopharma supports the launch of “Nature Italy”
The Company reaffirms and strengthens its commitment to research and innovation
Kedrion alongside AICE on the 50th Ann. of the first AICE Triennial Conference
The company supports the reading of a scientific study on the role of Factor VIII in the protection of the joints
Kedrion announces the appointment of a new CEO
Val Romberg from the USA, one of the most esteemed managers in the industry
KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH
Further step towards an even stronger focus on patients in Europe
Kedrion-Kamada collaboration, first patient enrolled in the clinical trial
Yet another milestone in the global Kedrion-Kamada collaboration for the development, manufacturing and distribution of a plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). On Aug. 10, 2020 Kamada Ltd. announced that the first patient has been recruited to the Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived immunoglobulin (IgG) product